Sermorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of the first 29 amino acids of endogenous GHRH — the minimal sequence required for full biological activity. Unlike CJC-1295 analogs, Sermorelin is structurally closer to native GHRH with a shorter half-life (~12 minutes), producing brief, physiologically-accurate GH pulses. It serves as an important comparator in GH axis research, particularly for studying natural vs. modified GHRH analog pharmacokinetics.
Research Applications
Native GHRH pharmacokinetic comparison studies
Brief, physiologic GH pulse research
Hypothalamic-pituitary axis investigations
GH secretion rhythm and pattern studies
Combination with GHRP synergy protocols
Quality Specifications
Purity: ≥98% (HPLC verified)
Compound: Sermorelin
Molecular Weight: 3357.9 Da
Form: Lyophilized powder
Storage: -20°C, protect from light
COA: Batch-specific, ISO-accredited laboratory
Frequently Asked Questions
Q: How does Sermorelin differ from CJC-1295? A: Sermorelin is native GHRH 1-29 with ~12-minute half-life. CJC-1295 No DAC is modified for ~30 minutes; DAC version is albumin-bound for days. Sermorelin is closest to physiological GHRH.
Q: Why use Sermorelin over modified analogs? A: When research requires studying native GHRH receptor activation without modified pharmacokinetics, Sermorelin provides the most physiologically accurate GH stimulation profile.
Q: Can Sermorelin be combined with GHRPs? A: Yes. Like other GHRH analogs, Sermorelin combines with GHRPs (Ipamorelin, GHRP-6) for synergistic GH release via dual-pathway activation.
